文献速递间质性肺疾病

无肌病性皮肌炎相关间质性肺病的死亡风险预测:FLAIR模型

Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model.
PubMed 文献 · Chest · 2020-05-16

这项前瞻性起始队列研究纳入207例无肌病性皮肌炎相关间质性肺病(ADM-ILD)患者,用多因素Cox模型建立FLAIR风险评分,包含铁蛋白、乳酸脱氢酶、抗MDA5抗体、高分辨率CT评分和快速进展型ILD五项。模型将患者分为低、中、高风险三组,在发现队列和验证队列中高风险组死亡率均显著高于低、中风险组(P < .001)。

要点

  • FLAIR评分含铁蛋白、LDH、抗MDA5抗体、HRCT评分和RPILD五项。
  • 评分0–4为低风险,5–9为中风险,10–13为高风险。
  • 高风险组死亡率显著高于低、中风险组(P < .001)。

核心结论

  • FLAIR风险评分模型有助于预测ADM-ILD患者的生存,并指导基于风险的临床治疗研究。

研究设计与样本

  • 前瞻性起始队列研究,评估207例ADM-ILD患者。
  • 用多因素Cox比例风险模型筛选独立预后危险因素并建立风险评分模型,建模数据为2012年1月至2016年12月的患者数据。
  • 采用基于Brier评分的预测准确度指数反映模型的区分度和校准度。
  • 模型在2017年1月至2018年6月的独立患者组中进行验证。

主要发现

  • FLAIR评分各项赋分:铁蛋白<636 ng/mL为0分、≥636 ng/mL为2分;乳酸脱氢酶<355 U/L为0分、≥355 U/L为2分;抗MDA5抗体阴性为0分、+为2分、++为3分、+++为4分;高分辨率CT评分<133为0分、≥133为3分;非RPILD为0分、RPILD为2分。
  • 按FLAIR评分分为三组:低风险0–4分、中风险5–9分、高风险10–13分。
  • 在发现队列和验证队列中,高风险患者死亡率均显著高于低风险和中风险患者(P < .001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognosis of amyopathic dermatomyositis (ADM)-associated interstitial lung disease (ILD) is poor. A mortality risk score model is needed to predict survival in patients with ADM-ILD and to guide clinical treatment. RESEARCH QUESTION: How to identify patients with ADM-ILD who are at high risk and to predict patient outcome based on a risk stratification model? STUDY DESIGN AND METHODS: We evaluated 207 patients with ADM-ILD in this prospective inception study. We used a multivariable Cox proportional hazards model to identify the independent prognostic risk factors and created a risk score model according to patient data from January 2012 to December 2016. We used the index of prediction accuracy that uses the Brier score to reflect both discrimination and calibration of the model. The model was validated in an independent group of patients from January 2017 to June 2018. RESULTS: We developed a combined risk score, the FLAIR score, that included the following values and scores: ferritin (<636 ng/mL, 0; ≥636 ng/mL, 2), lactate dehydrogenase (<355 U/L, 0; ≥355 U/L, 2), antimelanoma differentiation-associated gene 5 antibody (negative, 0; +, 2; ++, 3; +++, 4), high-resolution CT imaging score (<133, 0; ≥133, 3), and rapidly progressive ILD (RPILD) (non-RPILD, 0; RPILD, 2). We divided patients into three risk groups according to the FLAIR score: low, 0 to 4; medium, 5 to 9; and high, 10 to 13. In both discovery and validation cohorts, high-risk patients had significantly higher mortality rates than low- and medium-risk patients (P < .001). INTERPRETATION: The FLAIR risk score model could help to predict survival in patients with ADM-ILD and to guide further clinical research on risk-based treatment.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lian X, Zou J, Guo Q, et al. Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model. Chest. 2020. PMID: 32428508. doi:10.1016/j.chest.2020.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。